# ASPEN-05 (NCT04755244)

> A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

No report yet. It can be ordered.

- Drugs tested: evorpacept plus venetoclax plus azacitidine
- Indication: adult acute myeloid leukemia

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04755244
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: ALX Oncology Inc.
- Conditions: Acute Myeloid Leukemia; AML, Adult
- Interventions: evorpacept; venetoclax; azacitidine
- Enrollment: 14
- Primary outcome: Phase 1: Dose Limiting Toxicities (DLT)
- Primary outcome: Phase 2: Composite complete remission rate (CRc)

## Indexed commentary on ASPEN-05 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=aspen-05-nct04755244